Skip to main content

Advertisement

SpringerLink
Log in

Screening, Prevention, and Ambitious Management of Diabetic Macular Edema in Patients with Type 1 Diabetes

  • Treatment of Type 1 Diabetes (JR Unger, Section Editor)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Diabetic macular edema results from progressive retinopathy related to chronic hyperglycemic and inflammatory vascular damage. Loss of vision secondary to diabetic macular edema is the most common cause of vision loss in patients with diabetes. Blood glucose control remains the main means of preventing progression of retinopathy and macular edema. Recent advancements allowing more efficient mechanisms for screening patients and emerging treatments for macular edema have led to improved visual outcomes in this group of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102:647–61.

    Google Scholar 

  2. Klein R, Knudtson MD, Lee KE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116(3):497–503.

    Article  PubMed  Google Scholar 

  3. Schroder S, Palinski W, Schmid-Schonbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol. 1991;139:81–100.

    PubMed  CAS  Google Scholar 

  4. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: Pathogenesis and treatment. Surv Ophthalmol. 2009;54:1–32.

    Article  PubMed  Google Scholar 

  5. American Academy of Ophthalmology Retina Panel : Preferred practice pattern guidelines: diabetic retinopathy. San Francisco, American Academy of Ophthalmology, 2008. Available online from http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=d0c853d3-219f-487b-a524-326ab3cecd9a

  6. Centers for Disease Control and Prevention, Behavioral Risk Factor Surveillance System. The data was computed by CDC’s Division of Diabetes Translation personnel. Available online from http://www.cdc.gov/diabetes/statistics/preventive/fX_eye.htm

  7. ETDRS Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification (ETDRS report number 10). Ophthalmology. 1991;98(5 Suppl):786–806.

    Google Scholar 

  8. Harding SP, Broadbent DM, Neoh C, et al. Sensitivity and specificity of photography and direct ophthalmoscopy in screening for sight threatening eye disease: the Liverpool Diabetic Eye Study. BMJ. 1995;311:1131–5.

    Article  PubMed  CAS  Google Scholar 

  9. Olson JA, Strachan FM, Hipwell JH, et al. A comparative evaluation of digital imaging, retinal photography and optometrist examination in screening for diabetic retinopathy. Diabet Med. 2003;20:528–34.

    Article  PubMed  CAS  Google Scholar 

  10. Abràmoff MD, Reinhardt JM, Russell SR, et al. Automated early detection of diabetic retinopathy. Ophthalmology. 2010;117:1147–54.

    Article  PubMed  Google Scholar 

  11. Abràmoff MD, Folk JC, Han DP, et al. Automated analysis of retinal images for detection of referable diabetic retinopathy. JAMA Ophthalmol. 2013;131:351–7.

    Article  PubMed  Google Scholar 

  12. Williams GA, Scott IU, Haller JA, et al. Single-field fundus photography for diabetic retinopathy screening: a report by the American Academy of Ophthalmology. Ophthalmology. 2004;111:1055–62.

    Article  PubMed  Google Scholar 

  13. Bursell SE, Cavallerano JD, Cavallerano AA, et al. Joslin Vision Network Research Team : Stereo nonmydriatic digital-video color retinal imaging compared with Early Treatment Diabetic Retinopathy Study seven standard field 35-mm stereo color photos for determining level of diabetic retinopathy. Ophthalmology. 2001;108:572–85.

    Article  PubMed  CAS  Google Scholar 

  14. Cavallerano AA, Cavallerano JD, Katalinic P, et al. Joslin Vision Network Clinical Team : Use of Joslin Vision Network digital-video nonmydriatic retinal imaging to assess diabetic retinopathy in a clinical program. Retina. 2003;23:215–23.

    Article  PubMed  Google Scholar 

  15. DCCT Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102:647–61.

    Google Scholar 

  16. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

    Article  Google Scholar 

  17. Kohner EM, Stratton IM, Aldington SJ, et al. UK Prospective Diabetes Study (UKPDS) Group : Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med. 2001;18:178–84.

    PubMed  CAS  Google Scholar 

  18. UK Propspective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: (UKPDS 38). BMJ. 1998;317:703–13.

    Article  Google Scholar 

  19. Early Treatment Diabetic Retinopathy Study research group. P8otocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–806.

    Article  Google Scholar 

  20. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447–9. e1–10.

    Article  Google Scholar 

  21. • Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, et al. Three-year follow up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127:245–51. This study demonstrated that focal laser remains an essential component of DME management and has superior efficacy with fewer side effects than do intravitreal triamcinolone injections.

    Article  PubMed  Google Scholar 

  22. Kozak I, Oster SF, Cortes MA, et al. Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS. Ophthalmology. 2011;118:1119–24.

    Article  PubMed  Google Scholar 

  23. Lavinsky D, Cardillo JA, Melo LA, et al. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Investig Ophthalmol Visual Sci. 2011;52:4314–23.

    Article  Google Scholar 

  24. Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol. 2005;89:74–80.

    Article  PubMed  CAS  Google Scholar 

  25. Roider J, Liew SH, Klatt C, et al. Selective retina therapy (SRT) for clinically significant diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2010;248:1263–72.

    Article  PubMed  Google Scholar 

  26. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920–7.

    Article  PubMed  Google Scholar 

  27. Jonas JB, Akkoyun I, Kreissig I, Degenring RF. Diffuse diabetic macular edema treated by intravitreal triamcinolone acetonide: a comparative, non-randomized study. Br J Ophthalmol. 2005;89:321–6.

    Article  PubMed  CAS  Google Scholar 

  28. Campochiaro PA, Brown DM, Pearson A, FAME Study Group, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118:626–35.

    Article  PubMed  Google Scholar 

  29. Campochiaro PA, Brown DM, Pearson A, FAME Study Group, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125–32.

    Article  PubMed  Google Scholar 

  30. Hippenstiel S, Krull M, Ikemann A, et al. VEGF induces hyperpermeability by a direct action on endothelial cells. Am J Physiol. 1998;274:678–84.

    Google Scholar 

  31. Gragoudas ES, Adamis AP, Cunningham Jr ET. et al; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–16.

    Article  PubMed  CAS  Google Scholar 

  32. Elman MJ, Aiello LP, Beck RW, et al. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–77.

    Article  PubMed  Google Scholar 

  33. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14.

    Article  PubMed  Google Scholar 

  34. • Nguyen QD, Brown DM, Marcus DM, et al. RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801. This study was of particular importance and demonstrated that monthly ranibizumab significantly improved vision, reduced the risk of further vision loss, and improved macular edema in patients with DME.

    Article  PubMed  Google Scholar 

  35. Ip MS, Domalpally A, Wong P, Hopkins JJ. Effects of intravitreal ranibizumab on diabetic retinopathy severity: 36-month data from RISE and RIDE trials. Paper presented at: the American Academy of Ophthalmology Annual Meeting; November 12, 2012; Chicago, IL.

  36. Do DV, Nguyen QD, Boyer D, et al. DA VINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119:1658–65.

    Article  PubMed  Google Scholar 

  37. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report from the Diabetic Retinopathy Study. Ophthalmol. 1978;85:81–106.

    Google Scholar 

  38. Ferris 3rd FL, Podgor MJ, Davis MD. Macular edema in Diabetic Retinopathy Study patients. Diabetic Retinopathy Study Report Number 12. Ophthalmology. 1987;94:754–60.

    PubMed  Google Scholar 

  39. Shimura M, Yasuda K, Nakazawa T, et al. Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247:1617–24.

    Article  PubMed  CAS  Google Scholar 

  40. Wessel MM, Nair N, Aaker GD, et al. Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema. Br J Ophthalmol. 2012;96:694–8.

    Article  PubMed  Google Scholar 

  41. Gaucher D, Fortunato P, LeCleire-Collet A, et al. Spontaneous resolution of macular edema after panretinal photocoagulation in florid proliferative diabetic retinopathy. Retina. 2009;29:1282–8.

    Article  PubMed  Google Scholar 

  42. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99:753–9.

    PubMed  CAS  Google Scholar 

  43. Harbour JW, Smiddy WE, Flynn Jr HW, Rubsamen PE. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol. 1996;121:405–13.

    PubMed  CAS  Google Scholar 

  44. Pendergast SD, Hassan TS, Williams GA, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol. 2000;130:178–86.

    Article  PubMed  CAS  Google Scholar 

  45. Stefansson E, Landers MBI, Wolbarsht ML. Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy. Tr Am Ophth Soc. 1981;79:307–34.

    PubMed  CAS  Google Scholar 

  46. Diabetic Retinopathy Clinical Research Network Writing Committee, Haller JA, Qin H, Apte RS, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117:1087–93.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Ryan M. Tarantola declares that he has no conflict of interest.

Raj K Maturi has been a consultant for Bayer, Eli Lily & Co., Jaeb Center for Health Research, Regeneron; has given expert testimony for U.S. Attorney, DOJ, Erie Insurance, Workers’ Compensation, Patient Compensation Fund, Wilson, Cunningham & Kehoe, Mentor Planning & Consulting, Inc.; has received honoraria from Regeneron and Jaeb Center for Health Research; has received travel/accommodations expenses covered or reimbursed from Jaeb Center for Health Research, Regeneron, Mentor Planning, American Academy of Ophthalmologists. He has been a subinvestigator for Alcon, Alimera, Nexus, Quark Pharmaceuticals. He has been a principal investigator for Allergan, Sanofi-Aventis/FOV2304/Covance, Eyegate Pharmaceuticals, GlaxoSmithKline, Lux Biosciences, Jaeb Center for Health Research, Novagali, Parexel, Pfizer, Santen Global.

Shalesh Kushal has been a consultant for Alcon, Allergan, Pfizer, Novartis, OPKO, BIKAM and Sanofi.

Sunil Gupta is a consultant for Genentech, Allergan and Alcon. He has been a PI for clinical trials with Genentech, Alcon, Allergan, Santen, Acucela, Regeneron, Pfizer, Parexel, and Eye-tech. He is a principal in Intelligent Retinal Imaging Systems.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Retina Specialty Institute, 5150 N. Davis Highway, Pensacola, FL, 32503, USA

    Ryan M. Tarantola, Shalesh Kushal & Sunil Gupta

  2. Midwest Eye Institute, 200 W 103rd Street, Ste 1000, Indianapolis, IN, 46209, USA

    Raj K. Maturi

Authors
  1. Ryan M. Tarantola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raj K. Maturi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shalesh Kushal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sunil Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sunil Gupta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tarantola, R.M., Maturi, R.K., Kushal, S. et al. Screening, Prevention, and Ambitious Management of Diabetic Macular Edema in Patients with Type 1 Diabetes. Curr Diab Rep 13, 679–686 (2013). https://doi.org/10.1007/s11892-013-0410-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-013-0410-z

Keywords

Search

Navigation